TAR DNA-binding protein 43 (TDP-43) is the major disease protein of sporadic and familial frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U) with or without motor neuron disease (MND) as well as sporadic and the majority of familial amyotrophic lateral sclerosis (ALS) cases (1,2). Human TDP-43 is encoded by the TARDBP gene on Chromosome 1. It is a 414 amino acid nuclear protein with two highly conserved RNA recognition motifs (RRM1 and RRM2) and a C-terminal tail with a typical glycine-rich region that mediates protein-protein interactions, including interactions with other heterogeneous ribonucleoprotein (hnRNP) family members such as hnRNP A1, A2/B1 and A3 (3). Thus, TDP-43 is a ubiquitously expressed RNA/DNA binding protein that also interacts with other nuclear proteins such as splicing factors. As such, TDP-43 is implicated in repression of gene transcription, regulation of exon splicing and the functions of nuclear bodies (4-9).
TAR DNA-binding protein 43 (TDP-43) is the major disease protein of sporadic and familial frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U) with or without motor neuron disease (MND) as well as sporadic and the majority of familial amyotrophic lateral sclerosis (ALS) cases (1, 2) . Human TDP-43 is encoded by the TARDBP gene on Chromosome 1. It is a 414 amino acid nuclear protein with two highly conserved RNA recognition motifs (RRM1 and RRM2) and a C-terminal tail with a typical glycine-rich region that mediates protein-protein interactions, including interactions with other heterogeneous ribonucleoprotein (hnRNP) family members such as hnRNP A1, A2/B1 and A3 (3) . Thus, TDP-43 is a ubiquitously expressed RNA/DNA binding protein that also interacts with other nuclear proteins such as splicing factors. As such, TDP-43 is implicated in repression of gene transcription, regulation of exon splicing and the functions of nuclear bodies (4) (5) (6) (7) (8) (9) .
Pathological TDP-43 accumulates as insoluble aggregates in central nervous system neurons and glia of patients with FTLD-U and ALS (1) . Moreover, FTLD-U patients can develop ALS and ALS patients often suffer from a dementia consistent with FTLD-U (10). We therefore proposed that these diseases are part of a clinicopathological spectrum of the same neurodegenerative process collectively referred to as TDP-43 proteinopathy (1, 2) . TDP-43 inclusions are present as cytoplasmic, neuritic or nuclear inclusions and affected neurons show a dramatic depletion of normal nuclear TDP-43 (1, 11, 12) . To mimic this nuclear clearance and to model the sequestration of endogenous TDP-43 into cytoplasmic aggregates, we overexpressed TDP-43 with mutated nuclear localization signals (ΔNLS-TDP-43) in cultured cells that showed a reduction in endogenous nuclear TDP-43 and accumulations of insoluble cytoplasmic aggregates (13) . Moreover, overexpression of TDP-43 with a mutated nuclear export signal (ΔNES-TDP-43) resulted in the formation of insoluble nuclear TDP-43 aggregates (13) .
Pathological TDP-43 is hyperphosphorylated, ubiquitinated and abnormally cleaved so that C-terminal fragments (CTFs) of TDP-43 accumulate in cells of affected CNS areas (1) . Indeed, we recently showed that insoluble TDP-43 CTFs are selectively enriched in affected cortical regions compared with spinal cord of both FTLD-U and ALS cases (14) . These observations suggest that TDP-43 is differentially processed in brain versus spinal cord, and that TDP-43 CTFs might seed inclusion formation and aggregation in cortical neurons. Since CTFs contain the TDP-43 glycine-rich region, the accumulation of CTF-rich aggregates may result in abnormal interactions with proteins involved in the splicing machinery of affected cells. However, little is known about how pathological TDP-43 is cleaved to generate TDP-43 CTFs or the biochemical properties of disease-related TDP-43 CTFs.
Here we address these questions by identifying the cleavage site of an endogenous TDP-43 CTF purified from FTLD-U brains. We also model the aggregation of this and several other TDP-43 CTFs in the cytoplasm of cultured cells and show that expression of TDP-43 CTFs is sufficient to generate cytoplasmic aggregates. Moreover, these insoluble CTFs are ubiquitinated and abnormally phosphorylated at sites similar to those in human FTLD-U and ALS CNS samples. Finally, we demonstrate that cells expressing TDP-43 CTFs display abnormal splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) which is relevant to TDP-43 function since alternative splicing of this gene is known to be regulated by TDP-43 (6). Our results recapitulate unique features of pathological TDP-43 that are hallmarks of FTLD-U and ALS and implicate the generation of TDP-43 CTFs as a key event in the pathogenesis of TDP-43 proteinopathies.
EXPERIMENTAL PROCEDURES
Constructs. N-terminal truncations (see below) were generated by PCR of human TDP-43 using the following primers: 177-TDP-43, 5'GGATCCATGC TTCCTAATTCTAAGCAAAGCC-3'; 187-TDP-43, 5'-GGATCCATGC CTTTGAGAAGCAGAAAAGTGT-3'; 197-TDP-43, 5'-GGATCCA TGCGCTGTACAGAGGACATGACTG-3'; 208-TDP-43, 5'-GGATCCC GGGGTTCTTCTCTCAGTACGGGGAT-3', and 5'-TCTAGAG CTACATTCCCCAGCCAGAAGACTTAGA-3'. The addition of a myc epitope tag to the 5'-end of the TDP-43 N-terminal truncations was achieved by PCR, using the following primers; 5- Myc-177-TDP-43,  5'-GGATCCATGGAACAAAAACTCATCTCGGA  A  GAGGATCTGCTTCCT  AATTCTAAGCAAAGCC-3'; Myc-187-TDP-43,  5'-GGATCCATGGAACAAAAACTCATCTCGGA  AGAGGATCTGCCTTTGAGAAGCAGAAAAG  TGT-3';  Myc-197-TDP-43,  5'-GGATCCATGGAACAAAAACT  CATCTCGGAAGAGGATCTGCGCTGTACAG  AGGACATGACTG-3', Myc-208-TDP-43, 5'-GGATCCATGGAACAAAAACTCATCTCGGA AGAGGATCTGCGGGAGTTCTTCTCTCAGTA CGGGGAT-3, and 5'-TCTAGAG CTACATTCCCCAGCCAGAAGACTTAGA-3'. All PCR products were cloned into the pGEM-T vector (Promega, Madison, WI). Following sequence analysis the PCR products were subcloned into pcDNA 5/To plasmid (Invitrogen) using restriction sites BamHI and XbaI. A diagram of each TDP-43 CTF is shown in Fig. 1B . Myc-WT-TDP-43, Myc-ΔNLS-TDP-43 and Myc-ΔNES-TDP-43 were previously described (13) . Human TDP-43 shRNA (targeted to the 3' UTR region) was obtained from OriGene (Rockville, MD, Cat. No. TR308946). pcDNA 3.1 alphasynuclein was previously described (15) . Antibodies. Commercial antibodies used in this study were: rabbit anti-TDP-43 polyclonal (pAb) raised to aa 1-260 (Protein Tech Group, Chicago, IL), a human specific mouse monoclonal (mAb) raised to the same TDP-43 sequence (2E2-D3) (Abnova, Taipei, Taiwan), anti-myc mAb (9E10, Santa Cruz Biotechnology, Santa Cruz, CA), anti-HA (12CA5 mouse mAb, Roche Applied Bioscience, Indianapolis, IN) and anti-α-GAPDH (6C5 mouse mAb, Advanced ImmunoChemical Inc, Long Beach, CA). A rabbit anti-TDP-43 pAb raised to aa 394-414 (C-t TDP-43 pAb) was described previously (14) . A rat phospho-specific mAb that recognizes TDP-43 phosphorylated at Ser409/Ser410 (p409/410 TDP-43) was developed and characterized elsewhere (16 Immunofluorescence Studies. Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.2% Triton X-100 (Sigma) in PBS for 10 min, blocked with 5% powdered-milk in PBS for 2 hrs and incubated overnight with primary antibody at 4ºC. Primary antibodies were visualized with secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 594 (Vector Laboratories, Burlingame, CA) and nuclei were detected using DAPI. All cells were analyzed using a Nikon TE-2000-E (Nikon, Tokyo, Japan) and images were captured using a CoolSnap-HQ camera (Photometrics, Tuscon, AZ). All micrographs show images representative of the total cell population. For quantification of aggregates, several random fields per sample were analyzed and the percentage of transfected cells that displayed TDP-43 positive accumulations was calculated. Solubility and Biochemical Analysis. To examine the solubility profile of TDP-43, sequential extractions were performed. Cells were washed twice with PBS, lysed in cold RIPA buffer containing 1 mM PMSF, a cocktail of protease inhibitors (PI) (1 mg/ml Pepstatin, Leuptin, TPCK, TLCK, trypsin inhibitor; Sigma) and a cocktail of phosphatase inhibitors (PPI) (2 mM imidazole, 1 mM NaF, 1 mM sodium orthovanadate, Sigma). Cell lysates were sonicated and then cleared by centrifugation at 100,000 x g for 30 min at 4ºC to generate the RIPA soluble samples. To prevent carry-overs, the resulting pellets were washed with RIPA buffer (i.e. re-sonicated and re-centrifuged).
Only the supernatants from the first centrifugation were analyzed. RIPA insoluble pellets were then extracted with urea buffer (7M urea, 2M thiourea, 4% 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 30mM Tris, pH 8.5), sonicated and centrifuged at 70,000 x g for 30 min at 22ºC. Protease and phosphatase inhibitors were added to all buffers prior to use (1 mM PMSF and a cocktail of PI and PPI). Protein concentration was determined by bicinchoninic acid method (Pierce, Rockford, IL) and proteins were resolved by 10% or 15% SDS-PAGE and transferred to nitrocellulose membranes. Following transfer, nitrocellulose membranes were blocked in 5% powdered milk and incubated in the primary antibody overnight at 4ºC. Primary antibodies were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, Wegate, PA) and blots were developed with Renaissance Enhanced Luminal Reagents (NEN Life Science Products, Boston, MA). Digital images were acquired using a Fuji Film Intelligent Darkbox II (Fuji Systems, Stamford, CT). For quantification of TDP-43 CTFs insolubility, densitometric analysis of RIPAsoluble and insoluble fractions of at least 3 different experiments was performed using Image Quant 5.0 software (Molecular Dynamics Inc, Sunnyvale, CA). Where indicated, cell lysates or postmortem brain tissue from FTLD-U cases sequentially extracted as previously described (1) were dephosphorylated by dialysis (20 mmol/L Tris and 0.2 mmol/L EDTA, pH 8.0) and treated with Escherichia coli alkaline phosphatase (Sigma) for 2 hr at 56 ºC. Splicing analysis. TDP-43 functional activity was assayed through evaluation of CFTR splicing. First, various TDP-43 constructs were transiently transfected into QBI-293 cells using Lipofectamine 2000 reagent (Invitrogen) following standard manufacturer protocols. Fortyeight hr later, a hybrid minigene construct (a generous gift from Dr. F. Baralle, ICGEB, Trieste, Italy) designed to evaluate CFTR exon 9 splicing was transiently transfected into the same cells (6, 17) . Fig. S3B depicts the structure of the minigene construct, which consists of CFTR exon 9 with portions of the CFTR flanking introns inserted between exons from a hybrid fibronectinalpha-globin gene (18) . The relative exclusion of exon 9 in the presence of various TDP-43 constructs was then evaluated by primer extension from the flanking exons of exon 9. Total RNA was prepared from cells 72 hours after transfection of TDP-43 constructs and 24 hours after transfection of the TG(13)T(5) CFTR minigene reporter construct, and RT-PCR was performed using 3 μg of total RNA and 2 μm of the resulting cDNA as described previously (17). The primers used were: Bra2 TAGGATCCGGTCACCAGGAAGTTGGTTAA ATCA; a2-3 CAACTTCAAGCTCCTAAGCCACTGC. PCR conditions were as follows: 95º for 10 min (hot start), followed by 30 cycles of denaturing at 95º for 30 sec, annealing at 57º for 30 sec, and elongation at 72º for 60 sec. PCR products were visualized on a 1.5% agarose gel; relative amounts of different splice products were quantified and visualized using the Agilent 2100 Bioanalyzer on a DNA 1000 chip. Experiments were performed in duplicate and repeated at least three times.
RESULTS

N-terminally Cleaved Sites of TDP-43 CTFs.
Previously, we have shown that cortical TDP-43 inclusions in FTLD-U and ALS brains are composed predominantly of CTFs (14) . To better understand the biological significance of the CTFs, we determined their cleavage sites by N-terminal sequencing. Cortical urea extracts of FTLD-U brains containing high levels of CTFs were immunoprecipitated (IP) with anti-TDP-43 mAb and the resultant proteins were resolved on SDS-PAGE gels and immunoblotted with a polylconal antibody (pAb) raised to the extreme C-terminus (C-t) of TDP-43. Two protein bands with apparent Mr of ~24 kD and ~22 kD were recognized by the anti-C-t TDP-43 pAb (Fig. 1A) . The same bands were identified on Amido Black-stained duplicate PVDF blots and were excised for N-terminal sequencing (arrows in Fig. 1A) . Results from the ~22 kD band gave a primary sequence beginning at Arg 208 in TDP-43 (Fig 1A, arrow with asterisk), but no sequence was obtained from the ~24 kD band. Similar results were obtained from four separate experiments using two different FTLD-U cases. The identification of the Nterminus of a CTF together with our previous LC/MSMS studies on TDP-43 CTFs showing the presence of residues at the extreme C-terminus (1), allow us to conclude that we have identified a pathological TDP-43 fragment spanning amino acid residues 208-414 (designated as 208 TDP-43).
To study the biochemical properties of TDP-43 CTFs and to determine if the expression of these fragments recapitulated pathological features of authentic CTFs isolated from FTLD-U and ALS brains, we developed a series of vectors for expression in cultured cells. Plasmids containing the 208 TDP-43 CTF as well as slightly longer CTFs containing residues 177-414, 187-414 or 197-414 of TDP-43 (designated as 177 TDP-43, 187 TDP-43 and 197 TDP-43 respectively) were generated (Fig. 1B) . Each TDP-43 CTF cDNA was expressed in QBI-293 cells, a human embryonic kidney cell line, as well as N2a, a mouse neuroblastoma cell line, and the electrophoretic mobility of the fragments migrated between 20-25 kD (Fig. 1C) . Fig. 2A, 2B and S1A) . Quantitative immunoblotting showed that almost 100% of the two smaller TDP-43 CTFs are insoluble in RIPA and can only be extracted by urea (Fig. 2B) . However, expression of TDP-43 CTFs tagged with the myc epitope in QBI-293 cells (Fig. S2) increased their solubility when compared with their untagged counterparts (compare Figs. S1 and S2) .
TDP-43 CTFs Expressed in Cultured Cells
We also detected multiple immunobands (particularly those recovered in the urea fractions) upon expression of TDP-43 CTFs in cultured cells ( Figs. 2A and S1A) . Since pathological TDP-43 CTFs recovered from FTLD-U and ALS brains are hyperphosphorylated at multiple sites including hyperphosphorylation at Ser409 and Ser410 (p409/410), we asked if the CTFs expressed in transfected cells are also hyperphosphorylated (19) . Using a rat mAb specific for p409/410 (16), we found that all 4 TDP-43 CTFs displayed robust phospho-specific signals and that labeled phosphoimmunobands showed slower apparent electrophoretic mobility than the main protein band recognized by the anti-C-t TDP-43 pAb ( Figs. 2A and S1A , red asterisks highlight the same immunobands detected by C-t TDP-43 and p409/410 antibodies and the black asterisk identify the main protein band recognized only by the anti-C-t TDP-43 pAb). Significantly, although the electrophoretic mobility of non-phosphorylated 208 TDP-43 CTFs was close to 20 kD, the phosphorylated counterpart migrated at ~ 22 kD. Moreover, phosphorylated TDP-43 CTFs were detected only in the urea fraction, and phosphorylation at Ser409 and Ser410 was not seen in endogenous TDP-43 recovered from RIPA extractions ( Figs. 2A and S1A) . Thus, like pathological TDP-43 CTFs recovered from diseased brains, TDP-43 CTFs in our in vitro models are phosphorylated, and the phosphorylated TDP-43 CTFs are insoluble.
To characterize the morphology of these phosphorylated, insoluble TDP-43 CTFs, we conducted double label immunofluorescence analysis of transfected cells using anti-C-t TDP-43 pAb and the rat anti-p409/410 mAb. Phosphorylated Ser409/Ser410 was detected within C-t TDP-43-positive aggregates when each of the 4 TDP-43 CTFs was expressed (Figs. 2C and S1B). Phosphorylated endogenous nuclear TDP-43 was not seen in control or untransfected cells and foci of aggregated phosphorylated TDP-43 CTFs were observed within diffuse cytoplasmic TDP-43 immunoreactivity when longer, more soluble CTFs (e.g. 177 TDP-43) were expressed ( Fig. 2C and S1B) . Occasionally, we observed CTFs in the nucleus and we attribute this to the overexpression and small size of the CTFs. Finally, we also observed a direct correlation between the solubility of the TDP-43 CTFs and aggregate formation such that the more insoluble CTFs, i.e. 208 TDP-43, consistently showed increased percentage of inclusion-bearing cells with larger aggregates (Fig. 2B, 2D) . Similar results were obtained using a third cell line -COS-7 cells (data not shown).
To determine if the size of our phosphorylated TDP-43 CTFs expressed in cultured cells correspond to endogenous CTFs from FTLD-U brains, we compared the electrophoretic mobility of TDP-43 fragments expressed in N2a cells and showed that they resembled the pathological FTLD-U fragments (Fig. 3A) . Indeed, since the phosphorylated 208 TDP-43 fragment expressed in N2a cells comigrated with an immunoband at ~ 22 kD of TDP-43 CTFs from FTLD-U brains, we suggest that the origin of our N-terminal sequenced fragment beginning with Arg 208 came from a phosphorylated FTLD-U CTF (Fig. 3A) . Dephosphorylated TDP-43 CTFs from N2a cells also co-migrated with FTLD-U CTFs (Fig. 3B) . Therefore, although the exact cleavage sites of the larger TDP-43 CTFs from FTLD-U brains remain to be determined, the close resemblance of the electrophoretic migration of these fragments to those expressed in N2a cells suggest that the biochemical properties of the expressed fragments we observed here likely reflect that of pathological TDP-43 CTFs in disease brains.
To determine if full length TDP-43 expressed in the cytoplasm is also phosphorylated, we transfected mutant TDP-43 with defective nuclear localization signals (ΔNLS-TDP-43) that we characterized in a previous study (13) and found robust phosphorylation at Ser409/410 of ΔNLS-TDP-43 in the insoluble fraction (Fig. 4A,  4B) . Interestingly, phosphorylation of Ser409/410 was not detected in RIPA soluble ΔNLS-TDP-43 or overexpressed WT-TDP-43 in both the RIPA and urea fractions. Similar results were obtained using N2a cells (data not shown). Thus, phosphorylation of both full length and CTFs of TDP-43 at Ser409/410 is detected in the insoluble cytoplasmic aggregates. Taken together, these observations suggest a correlation between phosphorylation and insolubility, regardless whether TDP-43 accumulates as the full length protein or as CTFs in the cytoplasm.
TDP-43 CTF Aggregates are Ubiquitinated.
We recently showed that ubiquitin-positive TDP-43 inclusions in FTLD-U and ALS brains are enriched in TDP-43 CTFs (14) . Therefore, we investigated whether aggregated TDP-43 CTFs in transfected cells were also ubiquitinated. Immunofluorescence analysis of transfected N2a or QBI-293 cells displayed strong colocalization of aggregated TDP-43 with ubiquitin; this was not seen in non-transfected neighboring cells or vector-only transfected cells (Fig. 5A and data 5B) . Control immunoprecipitation reactions carried out using an unrelated antibody (anti-tau T46 mAb) showed little or no high MW smear, irrespective of TDP-43 CTF expression (data not shown). MG132 treatment after transfection greatly increased the abundance of ubiquitinated TDP-43 concomitant with TDP-43 CTF expression (Fig. 5B) . Lack of TDP-43-positive high MW smear in the TDP-43 immunoblot is likely due to relatively low levels of ubiquitinated CTFs and as such below the sensitivity for detection with this antibody. These results are consistent with the notion that exogenous expression of TDP-43 CTFs leading to the formation of cytoplasmic aggregates also results in increased ubiquitination.
Accumulation of TDP-43 CTFs Compromises RNA Splicing of CFTR.
One of the biological functions of TDP-43 described previously is the regulation of alternative splicing. In particular, exon skipping mediated through interactions of TDP-43 with GU-repeats in CFTR and ApoAII pre-mRNA transcripts has been reported (6,7), while the enhancement of exon inclusion for the SMN2 gene has been reported upon overexpression of TDP-43 (8) . To determine whether expression of TDP-43 CTFs had any impact on this known biological function of TDP-43, we analyzed splicing efficiency using a previously described minigene reporter system (Fig. S3A, S3B) (6) . In agreement with previous observations, control experiments in cells transfected with WT-TDP-43 or a TDP-43 shRNA demonstrate that TDP-43 overexpression or depletion (>90%) led to a decrease or an increase in CFTR exon 9 inclusion, respectively (Fig. 6A, 6B and S3C) . Surprisingly, expression of all four TDP-43 CTFs tested resulted in a decrease in exon-skipping activity relative to control-transfected cells, suggesting a loss-offunction consequence of CTF generation (Fig. 6A,  6B and S3C) . The expression of WT-TDP-43 protein, the knockdown of endogenous TDP-43, and expression of all 4 TDP-43 CTFs were confirmed in the same samples employed for RNA isolation using immunoblot analysis of transfected QBI-293 cells (Fig. S3A and S3D) . This effect was specific to the TDP-43 CTFs since parallel transfection of α-synuclein, a protein not known to affect RNA splicing, into the same cell line showed no impact on CFTR reporter splicing activity (data not shown). It is noteworthy that while these TDP-43 CTFs do not possess the first RNA-recognition motif (RRM1) required for efficient RNA and DNA binding, they still encode the entire C-terminal region containing the glycine-rich domain that is critical for interactions of TDP-43 with proteins displaying known splicing inhibitory activity such as hnRNPs (3, 20) . Taken together, these results provide the first evidence of impaired splicing regulatory activity in the presence of abnormal TDP-43 species associated with FTLD-U and ALS pathology.
DISCUSSION
Our study investigated the role of TDP-43 CTFs in the pathogenesis of two neurodegenerative TDP-43 proteinopathies, i.e. FTLD-U and ALS. To that end, we recovered pathological TDP-43 CTFs from FTLD-U brains and provided the identity of one fragment encompassing amino acid residues 208-414. We further showed that expression of either the 208-414 TDP-43 CTF or slightly longer CTFs in cell culture systems resulted in the formation of ubiquitinated and hyperphosphorylated CTF aggregates. Finally, we demonstrated that TDP-43 CTF accumulation alters the splicing pattern of the TDP-43 mRNA target CFTR. These findings show that the generation of CTFs is sufficient to initiate a number of events -cytoplasmic localization, ubiquitination, phosphorylation and aggregation of TDP-43 CTFs-that mirror TDP-43 proteinopathy, and that these events have functional consequences on gene splicing.
Structurally, it is not surprising that the Cterminal region of TDP-43 may be important in disease pathogenesis, as this region harbors several remarkable features. Although the general domain architecture of TDP-43 is similar to that of other RNA-binding proteins of the RRM family such as hnRNPs, in silico analysis of the extreme C-terminal portion of TDP-43 (PSIPRED Server (21)) indicates that this region displays little organized secondary structure. In this regard, although the full length protein contains typical motifs (i.e. RRMs and glycine-rich domains), CTFs of TDP-43 (such as those found in disease and modeled in this study) may be viewed as functionally different entities which share some commonalities with other proteins linked to neurodegeneration, such as alpha-synuclein. These comparatively disordered peptides are aggregation-prone if the right conditions or posttranslational modifications are present.
Genetically, TDP-43's C-terminal region is implicated in pathogenesis as well. The discovery of multiple ALS-associated TARDBP mutations that map almost exclusively to the Cterminal domain constitutes an intriguing reminder of the potential link between abnormal TDP-43 post-translational modification, localization or conformation, and the pathogenesis of TDP-43 proteinopathies (22) (23) (24) (25) . Interestingly, several of these reported mutations may create novel phosphorylation sites through substitution to serine, which could provide the basis for abnormal properties of mutated TDP-43. Testing of such a hypothesis awaits the availability of more human neuropathological material from TARDBP mutation patients.
In the experiments described here, we found TDP-43 CTFs to be relatively insoluble and aggregation-prone similar to recent results in yeast (26) . Specifically, the expression of a GFP-tagged TDP-43 construct encoding a CTF (188-414 TDP-43, similar to a CTF used in this study) in yeast led to the formation of cytoplasmic aggregates as well as cellular toxicity. Yeast and mammalian cells appear to show some important differences in their handling of TDP-43, however. For example, Nterminal fragments of TDP-43 used in the same yeast study remained in the nucleus and showed no apparent aggregation or effect on cell survival (26) . In contrast, N-terminal fragments of TDP-43 expressed in a mammalian cell culture system have been reported to mislocalize and form inclusions (27) . Unlike in yeast cells, epitopetagged TDP-43 CTFs are more soluble than their untagged counterparts when expressed in mammalian cells (Fig. S2B) . Thus, the biochemical profile of TDP-43 truncations appears to be sensitive to the cellular system used for study.
Our data show that expression of predominantly cytoplasmic species of TDP-43 (i.e. CTFs or NLS mutants) results in phosphorylation by an endogenous mechanism at residues that are pathologically hyperphosphorylated in human TDP-43 proteinopathies such as FTLD-U and ALS. Moreover, immunoblot and immunocytochemistry data showed that this abnormal phosphorylation is seen only with insoluble aggregated TDP-43. These data are compatible with a model of pathogenesis whereby cytoplasmic species of TDP-43 generated by proteolysis and/or redistribution become hyperphosphorylated and ubiquitinated. Other less likely possibilities include that hyperphosphorylation decreases solubility and promote aggregation or that more insoluble species are preferential substrates for yet to be determined protein kinases. Overall, our CTFs results suggest that proteolytic cleavage of TDP-43 may constitute an important event for aggregate formation, occurring independently or upstream of hyperhosphorylation.
If cytoplasmically localized, abnormally hyperphosphorylated and insoluble/aggregated CTFs are bona fide features of disease, what are their downstream functional consequences? This question is difficult to answer because the functions of normal TDP-43 remain incompletely understood. One relatively well-characterized biological function of TDP-43, however, is in the regulation of alternative splicing -specifically, the splicing of CFTR, Apo IIA, and SMN (6) (7) (8) . Of these, the most thoroughly studied splicing function of TDP-43 to date has been CFTR exon 9 skipping, which is mediated through (UG)m(U)n regulatory regions to which TDP-43 binds (6) . In the present study, we showed that expression of TDP-43 CTFs alters CFTR splicing, arguing that the generation of pathological CTFs affects normal TDP-43 function. We postulate that this effect may result from altered interactions with members of the hnRNP family of splicing factors. In vitro studies have determined that several members of the hnRNP family (A1, A2/B1, A3 and C1/C2) interact with TDP-43 through its C-terminal region (3) . Since hnRNP A/B proteins have known inhibitory splicing properties, the effect of TDP-43 on exon skipping could be mediated via recruitment of an hnRNP-rich inhibitory complex through its C-terminal tail (3, 28) . Given that several of these interactors have been shown to shuttle between the cytoplasm and the nucleus (29) , excess glycine-rich CTFs in the cytoplasm could alter the nucleocytoplasmic equilibrium of available hnRNP proteins, affecting not only TDP-43-mediated targets but also many different splicing and mRNA export pathways involving hnRNPs. Dysregulation of gene expression could then cause downstream disease effects in TDP-43 proteinopathies.
In this study, we investigated the hypothesis that TDP-43 CTFs are central to disease pathogenesis since they are seen in affected CNS regions from FTLD-U and ALS patients and absent in the CNS of normal individuals. By identifying Arg 208 as one of the cleavage sites of endogenous CTFs from FTLD-U brains and by demonstrating that this and other larger TDP-43 CTFs expressed in cultured cells co-migrate with pathological CTFs, we have generated TDP-43 CTF constructs to study the biochemical properties of the fragments. We showed that simply by expressing TDP-43 CTFs in a cell culture system, one can recapitulate key biochemical features of TDP-43 in disease -i.e. insolubility, aggregation, ubiquitination, and hyperphosphorylation. We also showed that expression of TDP-43 CTFs is sufficient to provoke a partial loss of one of the only known biological functions of TDP-43 -regulation of CFTR exon 9 splicing. These findings support the idea that generation of TDP-43 CTFs is an important event in FTLD-U and ALS pathogenesis. Thus, we believe that the cell culture model described here will be useful in identifying endogenous signaling cascades that lead to TDP-43 phosphorylation, assessing the impact of splicing alteration on cellular metabolism, and elucidating mechanisms of aberrant proteinprotein interaction displayed by pathological TDP-43 species. This information, in turn, will be vital in the development of targeted therapies for these neurodegenerative diseases. Representative agarose gel electrophoresis analysis of RT-PCR products used to assess CFTR exon 9 inclusion in TG13T5-transfected cells. QBI-293 were first transfected with either vector alone, WT TDP-43, a TDP-43 shRNA or TDP-43 CTFs and 48 hrs later, they were transfected with the TG13T5 CFTR reporter plasmid. After another 24 hrs, total RNA was isolated, and RT-PCR was performed using the primers indicated in Fig S3B. PCR products were visualized on agarose gels and quantified using the Agilent 2100 Bioanalyzer. Exon 9 included (+) and excluded (-) RT-PCR products are shown. The arrow indicates a previously reported aberrant splicing product (6) generated by a cryptic splicing site. (B) Spliced vs unspliced ratios were calculated and then normalized to the values of vector alone transfections. Mean values from at least 3 different experiments performed in duplicate are shown with S.E.M. * p< 0.05; ** p< 0.01; *** p<0.001 (Student t test vs. vector alone).
